John M. Reynolds

Commercial Rd
Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications

Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.

Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.

Journal: Rheumatology (Oxford, England)
Published: December 07, 2025

Cyclophosphamide and Cyclosporin for GVHD Prevention. Reply.

Cyclophosphamide and Cyclosporin for GVHD Prevention. Reply.

Journal: The New England journal of medicine
Published: October 01, 2025

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology
Published: September 14, 2025

Measurable residual disease intervention in AML: a new therapeutic horizon.

Measurable residual disease intervention in AML: a new therapeutic horizon.

Journal: Blood
Published: July 24, 2025

A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.

A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.

Journal: Blood advances
Published: July 01, 2025

A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.

A biomarker risk assessment tool predicts infection-related mortality after allogeneic stem cell transplantation.

Journal: Blood advances
Published: July 01, 2025

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin.

Journal: The New England journal of medicine
Published: June 13, 2025

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

Journal: Blood
Published: January 27, 2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Journal: Blood advances
Published: November 18, 2024

Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT).

Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT).

Journal: Blood advances
Published: September 23, 2024

Efficacy and Long-Term Outcomes of Eltrombopag Treatment Within 6 Months of Diagnosis in Patients With Steroid Unresponsive or Dependent Immune Thrombocytopenia.

Efficacy and Long-Term Outcomes of Eltrombopag Treatment Within 6 Months of Diagnosis in Patients With Steroid Unresponsive or Dependent Immune Thrombocytopenia.

Journal: American journal of hematology
Published: September 17, 2024

EXamining the feasibility of exerCisE to manage symptoms of Lupus (EXCEL): a protocol for a randomised controlled pilot study.

EXamining the feasibility of exerCisE to manage symptoms of Lupus (EXCEL): a protocol for a randomised controlled pilot study.

Journal: Lupus science & medicine
Published: September 06, 2024
Showing 1-12 of 110

Last Updated: 09/26/2026